Sanofi’s $1.7B rare disease gambit; CAR-T boxed warning saga; New biotechs on Nasdaq; A seller’s market for M&A?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Will the first two biotech IPOs of the year — both up­sized — pave the way for a rosy pub­lic mar­ket? How about the out­look for buy­outs? Don’t miss our analy­sis on these top­ics, and stay tuned as we find out Big Phar­ma’s view at earn­ings next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.